In a phase II clinical trial including 47 non-diabetic patients with impaired glucose tolerance, the BGP-15 treatment group demonstrated enhanced insulin sensitivity, and the drug was safe and well-tolerated.540 However, a phase II experiment that examined the safety and effectiveness of BGP-15 in T2DM patients was stopped early for lack of findings (NCT01069965). This evidence concerns the gene INS and type 2 diabetes mellitus.